Psychedelic stocks have exploded on news of the Compass Pathways IPO. Three companies are leading the charge.
Psychedelic stocks have exploded on news of the Compass Pathways IPO. Three companies are leading the charge.
Kevin O’Leary won’t touch cannabis as an investment but he loves the potential of psychedelic drugs. Why?
Mydecine Innovation's Mindleap subsidary launches a telehealth platform for psychedelics.
Move over Big Pharma, Here Comes Silicon Valley Investment In Psychedelics Stocks Like Compass Pathways (CMPS)
Numinus starts psilocybon cultivation operations in its 7,000 sq ft Health Canada-licensed facility.
New research initiative will compare the efficacy of psilocybin with LSD.
Mind Cure adds a health supplements veteran to its product development team. Moonbeam mushrooms in final product testing.
After a quiet summer, trading volumes are soaring as investors pile back into psychedelic stocks.
Compass Pathways has closed its IPO financing, raising $146.6 million via the sale of 8,625,000 American Depository Shares.
Mind Cure's organic Moonbeam mushroom products are now eligible for sale in Canada.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now